Диссертация (1140935), страница 30
Текст из файла (страница 30)
/ T. Eleftheriadis, V. Liakopoulos, K. Leivaditis, G.Antoniadi, I. Stefanidis. // Hippokratia. – 2011 – Vol. 15 (2). – Р. 120-126.123.ElKelany,M.A. Immunomodulatoryeffectsofsecondaryhyperparathyroidism on circulating CD4+ and CD8+ T-lymphocytes in chronicrenal failure patients. / M.A. El Kelany, S.S. Maklad, D.F. El Fouhil, E.A. ElEtreby, L.H. Saleh, N.A. El Sheikh. // Egypt. J. Immunol. – 2009. – Vol.
16 (2). –P. 71-82.124.Emam, A.A. Inflammatory biomarkers in patients with asymptomaticprimary hyperparathyroidism. / A.A. Emam, S.G. Mousa, K.Y. Ahmed, A.A. AlAzab // Medical Principles and Practice. – 2012. – Vol.21, № 3. – P. 249–253.125.Epstein, S. Effect of the interaction of parathyroid hormone andcyclosporine a on bone mineral metabolism in the rat. / S. Epstein, I.R.Dissanayake, G.R. Goodman, A.R. Bowman, H. Zhou, Y. Ma, W.S.
Jee.// Calcified Tissue International. – 2001. – Vol. 68. – P. 240–247.126.Erdogan, C. The evaluation of oxidative stress in patients with chronicrenal failure. / C. Erdogan, Y. Ünlücerci, A. Türkmen [et al.] // Clin. Chim. Acta.– 2002. – Vol. 322. – P.157–161.127.Esbrit, P. Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapies. / P.
Esbrit, M.J. Alcaraz //Biochem. Pharmacol. – 2013. – Vol. 85. – P. 1417–1423.186128.Esposito, R. Toxicity in uremia 2. Correlation between PTH levels andimpaired aspecific immunity. / R. Esposito, C. Romano-Carratelli, N. Lanzetti [etal.] // International Journal of Artificial Organs. – 1988. – Vol. 11 (3). – P. 159–160.129.Fallahzadeh, M.K. Interleukin-2 serum levels are elevated in patients withuremic pruritus: a novel finding with practical implications.
/ M.K. Fallahzadeh ,J. Roozbeh, B. Geramizadeh, M.R. Namazi // Nephrol. Dial. Transplant. – 2011. Vol. 26. – Iss. 10 - P. 3338-3344.130.Farahnak, P. Mild primary hyperparathyroidism: vitamin D deficiency andcardiovascular risk markers. / P. Farahnak, G. Lärfars, M. Sten-Linder, I-L.Nilsson // Journal of Clinical Endocrinology and Metabolism. -2011. – Vol. 96,№7.
– P. 2112–2118.131.Farahnak, P. Parathyroid hormone's acute effect on vasodilatory function. /P. Farahnak, L. Lind, K. Mattala, I.L. Nilsson. // Clin. Med. Insights Endocrinol.Diabetes. – 2010. – Vol. 3. – P. 37-42.132.Faul, C. FGF23 induces left ventricular hypertrophy. / C.
Faul, A.P.Amaral, B. Oskouei [et al.] // J. Clin. Invest. – 2011. - Vol. 121, № 11. – P. 4393–4408.133.Fernández-Fresnedo, G. B lymphopenia in uremia is related to anaccelerated in vitro apoptosis and dysregulation of Bcl-2. / G. FernándezFresnedo, M.A. Ramos, M.C. González-Pardo, A.L.
de Francisco, M. LopezHoyos, M. Arias // Nephrol. Dial. Transplant. – 2000. – Vol. 15. – P. 502–510.134.Finco, D.R. Effects of parathyroidectomy on induced renal failure in dogs./ D.R. Finco, S.A. Brown, W.A. Crowell [et al.] // Am. J. Vet. Res. – 1997. Vol. 58(2). – P. 188–195.135.Friedl, G.
Intermittent parathyroid hormone (PTH) treatment and age-dependent effects on rat cancellous bone and mineral metabolism. / G. Friedl,R.T. Turner, G.L. Evans, H. Dobnig // Journal of Orthopaedic Research. – 2007.– Vol. 25. – P. 1454–1464.136.Friedman, E.A. Intact antibody response to pneumococcal capsular187polysaccharides in uremia and diabetes. / E.A. Friedman, M.M. Beyer, S.R.Hirsch, G. Schiffman // Journal of the American Medical Association. – 1980.
–Vol. 244 (20). – P. 2310–2311.137.Funk, J.L. Expression of parathyroid hormone-related protein and theparathyroid hormone/parathyroid hormone-related protein receptor in rat thymicepithelial cells. / J.L. Funk, G.V. Jones, C.A. Botham, G. Morgan, P. Wooding,M.D. Kendall // J. Anat. – 1999. – Vol. 194 (Pt 2). – P. 255-264.138.Gaciong, Z. Impaired in vivo antibody production in CRF rats: role ofsecondary hyperparathyroidism. / Z. Gaciong, J.M. Alexiewicz, S.G. Massry //Kidney Int. – 1991. – Vol. 40 (5).
– P. 862-867.139.Gaciong, Z. Inhibition of immunoglobulin production by parathyroidhormone. Implications in chronic renal failure. / Z. Gaciong, J.M. Alexiewicz, M.Linker-Israeli, I.A. Shulman, T.O. Pitts, S.G. Massry. // Kidney Int. – 1991. –Vol. 40 (1). – P. 96-106.140.Galitzer, H. Parathyroid cell resistance to fibroblast growth factor 23 insecondary hyperparathyroidism of chronic kidney disease.
/ H. Galitzer, I.Z.Ben-Dov, J. Silver [et al.] // Kidney Int. – 2010. – Vol. 77, № 3. – P. 211–218.141.Galvao, J.F.B. Calcitriol, calcidiol, parathyroid hormone, and fibroblastgrowth factor-23 interactions in chronic kidney disease. / J.F.B. Galvao, L.A.Nagode, P.A. Schenck, D.J. Chew. // J.
Vet. Emerg. Crit. Care (San Antonio). –2013.- March, Vol. 23, № 2. – P. 134–162.142.Gandhi, S. Can parathyroid hormone be used as a biomarker for heartfailure? / S. Gandhi, R.B. Myers. // Heart Failure Reviews. – 2013. – Vol. 18. – P.465–473.143.Gao, P. Evolution of the parathyroid hormone (PTH) assay--importance ofcirculating PTH immunoheterogeneity and of its regulation. / P. Gao, P. D'Amour// Clin. Lab.
– 2005. – Vol. 51 (1-2). – P. 21-29.144.Gardella, T.J. Converting parathyroid hormone-related peptide (PTHrP)into a potent PTH-2 receptor agonist. / T.J. Gardella, M.D. Luck, G.S. Jensen,T.B. Usdin, H. Juppner // Journal of Biological Chemistry. – 1996. – Vol. 271. –188P. 19888–19893.145.Geara, A.S.
Effects of parathyroid hormone on immune function[Electronic resource] / A.S. Geara, M.R. Castellanos , C. Bassil, G. SchullerLevis , E. Park, M. Smith, M. Goldman, S. Elsayegh // Clin. Dev. Immunol. –2010. -vol. 2010 - Article ID 418695 - 10 pages, doi:10.1155/2010/418695146.Gebhardt, C.
S100A8 and S100A9 in inflammation and cancer. / C.Gebhardt, J. Nemeth, P. Angel, J. Hess. // Biochem. Pharmacol. – 2006. Vol. 72.P. 1622–1631.147.Giacchino, F. Parathyroid hormone as a uremic toxin: its influence on Tlymphocyte receptors. / F. Giacchino, G.
Quattrocchio, G. Piccoli // ClinicalNephrology. – 1985. – Vol. 23 (2). – P. 105–106.148.Gittes, R.F. Experimental model for hyperparathyroidism: effect ofexcessive numbers of transplanted isologous parathyroid glands. / R.F.Gittes, I.C. Radde // J. Urol. – 1966. – Vol. 95 (5). – P.: 595-603.149.Girndt, M. Defective expression of B7-2 (CD86) on monocytes of dialysispatients correlates to the uremia-associated immune defect.
/ M. Girndt, M.Sester, U. Sester, H. Kaul, H. Köhler // Kidney International. – 2001. – Vol. 59(4). – P. 1382–1389.150.Girndt, M. Molecular aspects of T- and B-cell function in uremia / M.Girndt, M. Sester, U. Sester [et al.] // Kidney Int. Suppl. – 2001. – Vol. 78. – S.206-211.151.Girndt, M. Production of interleukin-6, tumor necrosis factorα andinterleukin-10 in vitro correlates with the clinical immune defect in chronichemodialysis patients. / M. Girndt, H. Kohler, E. Schiedhelm-Weick, J.F.Schlaak, K-H. Meyer Zum Buschenfelde, B. Fleischer // Kidney International.
–1995. – Vol. 47 (2). – P. 559–565.152.Girndt, M. Tetanus immunization and its association to hepatitis Bvaccination in patients with chronic renal failure. / M. Girndt, M. Pietsch, H.Kohler. // American Journal of Kidney Diseases. – 1995. – Vol. 26 (3). – P. 454–460.189153.Grey, A. Circulating levels of interleukin-6 and tumor necrosis factor-α areelevated in primary hyperparathyroidism and correlate with markers of boneresorption—a clinical research center study.
/ A. Grey, M-A. Mitnick, S. Shapses,A. Ellison, C. Gundberg, K. Insogna // Journal of Clinical Endocrinology andMetabolism. – 1996. Vol. 81, № 10. P. 3450–3454.154.Griveas, I. Cellular immunity and levels of parathyroid hormone in uremicpatients receiving hemodialysis / I. Griveas, G. Visvardis, D. Papadopoulou [etal.] // Ren. Fail. – 2005. – Vol. 27. – Р. 275-278.155.Günal, S.Y. The assessment of oxidative stress on patients with chronicrenal failure at different stages and on dialysis patients receiving differenthypertensive treatment. / S.Y.
Günal, B. Ustündağ, A.İ. Günal // Indian J. Clin.Biochem. – 2013. – Vol. 28 (4). – P. 390-395.156.andGuo, C-Y. Immediate changes in biochemical markers of bone turnovercirculatinginterleukin-6afterparathyroidectomyforprimaryhyperparathyroidism. / C-Y. Guo, P.A. Holland, B.F. Jackson [et al.] // EuropeanJournal of Endocrinology. – 2000. – Vol. 142, № 5.
– P. 451–459.157.Guo, J. Phospholipase C signaling via the parathyroid hormone(PTH)/PTH-related peptide receptor is essential for normal bone responses toPTH. / J. Guo, M. Liu, D. Yang, M.L. Bouxsein, C.C. Thomas, E. Schipani, F.R.Bringhurst, H.M. Kronenberg // Endocrinology.
– 2010. – Vol. 151 (8). – P.3502-3513.158.Guimarães, G.N. Parathyroid hormone (1-34) modulates odontoblastproliferation and apoptosis via PKA and PKC-dependent pathways. / G.N.Guimarães, T.L. Rodrigues, A.P. de Souza, S.R. Line, M.R. Marques // Calcif.Tissue Int. – 2014. - Vol. 95 (3). – P. 275-281.159.Gutiérrez, O.M. Fibroblast growth factor 23 and disordered vitamin Dmetabolism in chronic kidney disease: updating the "trade-off" hypothesis. / O.M.Gutiérrez // Clin. J. Am.
Soc. Nephrol. – 2010, Sep. – Vol. 5(9). – P. 1710-1716.160.Habener, J.F. Parathyroid hormone: Biochemical aspects of biosynthesis,secretion, action, and metabolism. / J.F. Habener, M. Rosenblatt, J.T. Potts, Jr.190// Physiol. Rev. – 1984. – Vol. 64. – P. 985–1053.161.Halabe, A. Effect of parathyroid adenoma excision on interleukin-6 (IL-6)and IL-2 receptor levels. / A. Halabe, B. Shohat // Metabolism: Clinical andExperimental. – 2000. – Vol. 49, № 2. – P. 192–194.162.Halici, Z.
Protective effects of amlodipine and lacidipine on ovariectomy–induced bone loss in rats. / Z. Halici, B. Borekci, Y. Ozdemir, E. Cadirci, H.Suleyman //Eur. J. Pharmacol.– 2008.– Vol. 579(1–3).– P.– 241–245.163.Haÿ, E. N-cadherin interacts with axin and LRP5 to negatively regulateWnt/beta-catenin signaling, osteoblast function, and bone formation. / E.
Haÿ, E.Laplantine, V. Geoffroy, M. Frain, T. Kohler, R. Müller, P.J. Marie // Mol. Cell.Biol. – 2009. – Vol. 29. – P. 953–964.164.Hjelmesæth, J. Parathyroid hormone, but not vitamin D, is associated withthe metabolic syndrome in morbidly obese women and men: a cross-sectionalstudy. / J. Hjelmesæth, D.
Hofsø, E.T. Aasheim [et al.] //CardiovascularDiabetology. – 2009. – Vol. 8, article 7.165.Holtzman, S. A genetic predisposition to produce low levels of IL-10 isrelated to depressive symptoms: A pilot study of patients with end stage renaldisease / S. Holtzman, S.E. Abbey, C. Chan, J.M. Bargman, D.E. Stewart. //Psychosomatics. - 2012. – Vol. 53. – P. 155–161.166.Hori, M. Minireview: fibroblast growth factor 23 in phosphatehomeostasis and bone metabolism. / M.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
